ASCAT Conferences - VJHemOnc

VJHemOnc

The Video Journal of Hematology and Hematological Oncology

The assessment and management of pain in patients with Thalassaemia

Perla Eleftheriou

The assessment and management of pain in patients with Thalassaemia

Upcoming novel agents for the treatment of sickle cell disease

Perla Eleftheriou

Upcoming novel agents for the treatment of sickle cell disease

GBT_HOPE trial: patient experiences of voxelotor as a treatment for SCD

Perla Eleftheriou

GBT_HOPE trial: patient experiences of voxelotor as a treatment for SCD

Global initiatives in SCD and the role of the Lancet Commission

Subarna Chakravorty

Global initiatives in SCD and the role of the Lancet Commission

The future of SCD and Thalassaemia HSCT: partially matched donors

Lawrence Faulkner

The future of SCD and Thalassaemia HSCT: partially matched donors

Luspatercept and mitapivat for the treatment of patients with beta-thalassaemia

Maria Domenica Cappellini

Luspatercept and mitapivat for the treatment of patients with beta-thalassaemia

The importance of RBC exchange transfusions for managing fat embolism syndrome in SCD

Perla Eleftheriou

The importance of RBC exchange transfusions for managing fat embolism syndrome in SCD

Sickle Cell disease care in Lebanon

Sickle Cell disease care in Lebanon

Diverse participation in SCD blood group genotyping for improved transfusion outcome

Diverse participation in SCD blood group genotyping for improved transfusion outcome

Results of the BELIEVE study: luspatercept for the treatment of beta-thalassaemia

Maria Domenica Cappellini

Results of the BELIEVE study: luspatercept for the treatment of beta-thalassaemia

Gene therapy for the treatment of SCD: benefits and considerations

Andrew Campbell

Gene therapy for the treatment of SCD: benefits and considerations

Comparing adverse pregnancy outcomes in patients with SCD vs anemia

Comparing adverse pregnancy outcomes in patients with SCD vs anemia

The current landscape of SCD treatment

The current landscape of SCD treatment

Defining global strategies to improve outcomes in SCD

Mariane De Montalembert

Defining global strategies to improve outcomes in SCD

Addressing racism and stigma in the fields of SCD and Thalassaemia

Addressing racism and stigma in the fields of SCD and Thalassaemia

Pyruvate kinase activators for the treatment of Thalassaemia

Maria Domenica Cappellini

Pyruvate kinase activators for the treatment of Thalassaemia

Developing a test for SCD

Developing a test for SCD

Gene therapy approaches to treating SCD and Thalassaemia

Gene therapy approaches to treating SCD and Thalassaemia

Non-pharmacological pain management strategies in children with SCD

Non-pharmacological pain management strategies in children with SCD

Emerging drug targets for SCD

Emerging drug targets for SCD

Gene therapy: the future of SCD treatment?

Crawford Strunk

Gene therapy: the future of SCD treatment?

An update on curative treatments for patients with Thalassaemia

Maria Domenica Cappellini

An update on curative treatments for patients with Thalassaemia

Blood group genotyping program to improve transfusion outcomes in hemoglobinopathies

Blood group genotyping program to improve transfusion outcomes in hemoglobinopathies

Bone Marrow Quality Index to assess the safety of HSCT in Thalassaemia

Lawrence Faulkner

Bone Marrow Quality Index to assess the safety of HSCT in Thalassaemia

Age-related complications in SCD

Mariane De Montalembert

Age-related complications in SCD

Management of pregnant patients with SCD

Management of pregnant patients with SCD

Overcoming the financial challenge of gene therapy for SCD

Subarna Chakravorty

Overcoming the financial challenge of gene therapy for SCD

Treatment of patients with SCD who are not eligible for transfusion

Treatment of patients with SCD who are not eligible for transfusion

Treating SCD and Thalassaemia, the need for early diagnosis and access to treatment

Treating SCD and Thalassaemia, the need for early diagnosis and access to treatment

Improved life expectancy of patients with Thalassaemia and the challenges this presents

Maria Domenica Cappellini

Improved life expectancy of patients with Thalassaemia and the challenges this presents

ERN-EuroBloodNet and SCD management in Europe

Mariane De Montalembert

ERN-EuroBloodNet and SCD management in Europe

Genetic variants in SCD

Genetic variants in SCD

The Lancet Commission on SCD: global strategies to improve outcomes

The Lancet Commission on SCD: global strategies to improve outcomes

Determinants of severity in SCD

Determinants of severity in SCD

An approach for determining biomarkers in SCD

An approach for determining biomarkers in SCD

Using consumer wearables to predict pain in patients with SCD

Using consumer wearables to predict pain in patients with SCD

Prophylactic antibiotic use prior to dental treatment in SCD patients

Prophylactic antibiotic use prior to dental treatment in SCD patients

STArT trial: arginine in the treatment of SCD pain

Andrew Campbell

STArT trial: arginine in the treatment of SCD pain

The challenges of transitioning from pediatric to adult care in SCD

Mariane De Montalembert

The challenges of transitioning from pediatric to adult care in SCD

The barriers to gene therapy implementation for treating SCD in low- and middle-income countries

Lawrence Faulkner

The barriers to gene therapy implementation for treating SCD in low- and middle-income countries

Current trials in pregnant patients with SCD

Current trials in pregnant patients with SCD

Currently approved therapies for treatment of SCD

Currently approved therapies for treatment of SCD

An update on treatment of SCD

An update on treatment of SCD

The current landscape of Thalassaemia treatment

Subarna Chakravorty

The current landscape of Thalassaemia treatment

The importance of ASCAT 2023

The importance of ASCAT 2023

Machine learning prediction of 30-day hospital re-admission for vaso-occlusive crisis in SCD patients

Machine learning prediction of 30-day hospital re-admission for vaso-occlusive crisis in SCD patients

Genetic modifiers affecting the response to hydroxyurea in children with SC anemia

Genetic modifiers affecting the response to hydroxyurea in children with SC anemia

Investigating erythropoiesis and the bone marrow niche in SCD

Investigating erythropoiesis and the bone marrow niche in SCD

The Lancet Commission on SCD

The Lancet Commission on SCD

Proposed biomarkers of acute pain in SCD derived from longitudinal transcriptomics

Proposed biomarkers of acute pain in SCD derived from longitudinal transcriptomics

Addressing infertility risks in patients with SCD

Addressing infertility risks in patients with SCD

Managing the shift from pediatric to adult SCD care

Crawford Strunk

Managing the shift from pediatric to adult SCD care

Addressing access to pain relief for patients with SCD

Andrew Campbell

Addressing access to pain relief for patients with SCD

Cure2Children: delivering transplant therapy for SCD and Thalassaemia in developing countries

Lawrence Faulkner

Cure2Children: delivering transplant therapy for SCD and Thalassaemia in developing countries

Disease-modifying and curative SCD treatment updates from ASCAT 2023

Subarna Chakravorty

Disease-modifying and curative SCD treatment updates from ASCAT 2023

ASCAT 2023: goals and current projects

ASCAT 2023: goals and current projects

Privacy Policy

Site Designed and Built by MCI ©ASCAT